| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/15/2002 | WO2002062841A2 Secreted proteins |
| 08/15/2002 | WO2002062840A1 INTERFERON-α INDUCED GENE |
| 08/15/2002 | WO2002062810A2 Linkable sialyl lewis x analogs |
| 08/15/2002 | WO2002062799A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents |
| 08/15/2002 | WO2002062798A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 08/15/2002 | WO2002062789A1 Pyrazole compounds useful as protein kinase inhibitors |
| 08/15/2002 | WO2002062750A1 Cannabinoid receptor ligands |
| 08/15/2002 | WO2002062745A1 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity |
| 08/15/2002 | WO2002062423A1 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 08/15/2002 | WO2002062422A1 Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof |
| 08/15/2002 | WO2002062391A2 Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea |
| 08/15/2002 | WO2002062390A1 Medicinal compositions for treating lower uropathy |
| 08/15/2002 | WO2002062388A1 Composition and method for potentiating drugs |
| 08/15/2002 | WO2002062383A2 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases |
| 08/15/2002 | WO2002062377A2 Combined use of factor vii polypeptides and factor viii polypeptides |
| 08/15/2002 | WO2002062376A1 Combined use of factor vii polypeptides and factor ix polypeptides |
| 08/15/2002 | WO2002062375A1 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| 08/15/2002 | WO2002062369A2 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| 08/15/2002 | WO2002062367A1 Medical composition for managing hormone balance |
| 08/15/2002 | WO2002062362A2 Antiviral and antibacterial composition |
| 08/15/2002 | WO2002062361A1 Antiviral composition containing propolis and essential oils |
| 08/15/2002 | WO2002062357A1 Methods and devices for tissue repair |
| 08/15/2002 | WO2002062353A1 Composition containing sucrafate and a topical anesthetic for human and animals and method of use thereof |
| 08/15/2002 | WO2002062350A1 Methods for the administration of amifostine and related compounds |
| 08/15/2002 | WO2002062343A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS |
| 08/15/2002 | WO2002062342A1 A method for the treatment of heart failure |
| 08/15/2002 | WO2002062335A2 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| 08/15/2002 | WO2002062332A1 Pharmaceutical composition for treating multiple sclerosis |
| 08/15/2002 | WO2002062324A2 A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease |
| 08/15/2002 | WO2002062323A2 Use of mglur5 antagonists for the treatment of pruritic conditions |
| 08/15/2002 | WO2002062322A2 Glycine betaine and its use as anti-hemorrhagic agent |
| 08/15/2002 | WO2002062315A1 Rapid-onset medicament for the treatment of sexual dysfunction |
| 08/15/2002 | WO2002062306A1 Nos inhibitors for treatment of wrinkles |
| 08/15/2002 | WO2002062297A2 Methods and compositions for modulating gluconeogenesis using pgc-1 |
| 08/15/2002 | WO2002062293A2 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof |
| 08/15/2002 | WO2002062212A2 A personal condition management system |
| 08/15/2002 | WO2002062205A2 Methods for diagnosing and treating heart disease |
| 08/15/2002 | WO2002062204A2 Methods for diagnosing and treating heart disease |
| 08/15/2002 | WO2002046404A9 Schizophrenia-related voltage-gated ion channel gene and protein |
| 08/15/2002 | WO2002042265A3 Cyanoguanidine prodrugs |
| 08/15/2002 | WO2002039948A3 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| 08/15/2002 | WO2002038035A3 Methods for inhibiting pain |
| 08/15/2002 | WO2002032419A3 Methods for modulating bladder function |
| 08/15/2002 | WO2002028434A3 Use of a ppar delta activator for treating inflammatory conditions |
| 08/15/2002 | WO2002028433A3 Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition |
| 08/15/2002 | WO2002026729A3 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 08/15/2002 | WO2002022212A8 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 08/15/2002 | WO2002022160A3 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 08/15/2002 | WO2002018554A3 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof |
| 08/15/2002 | WO2002018369A3 Peptidomimetic protease inhibitors |
| 08/15/2002 | WO2002016381B1 Composition and method for inhibiting platelet aggregation |
| 08/15/2002 | WO2002014870A3 Use of antibodies against specific mhc-peptide complexes |
| 08/15/2002 | WO2002013793A3 Method of making tablets and tablet compositions produced therefrom |
| 08/15/2002 | WO2002013763A3 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 08/15/2002 | WO2002003815A3 Composition for the treatment of migraine |
| 08/15/2002 | WO2002000195A3 Methods and compositions for treating pain of the mucous membrane |
| 08/15/2002 | WO2002000175A3 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 08/15/2002 | WO2001091764A3 Extracts from spermatophyte plants with immunomodulating activity |
| 08/15/2002 | WO2001089448A3 Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects |
| 08/15/2002 | WO2001087285A3 Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors |
| 08/15/2002 | WO2001085995A9 Identification of neural defects associated with the nucleosom al assembly protein 1l2 gene |
| 08/15/2002 | WO2001085153A3 Potentiation of antineoplastic agents using sigma-2 ligands |
| 08/15/2002 | WO2001084961A3 Preparation for the prevention and/or treatment of vascular disorders |
| 08/15/2002 | WO2001080843A3 Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| 08/15/2002 | WO2001072685B1 Polyamine analogues as cytotoxic agents |
| 08/15/2002 | WO2001066753A3 Human genes and gene expression products |
| 08/15/2002 | WO2001061039A3 5-hydroxytryptamine transporter gene polymorphisms |
| 08/15/2002 | WO2001040309A9 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
| 08/15/2002 | WO2001039765A9 Compositions and methods for the induction and treatment of retinal detachments |
| 08/15/2002 | WO2001032877A9 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 08/15/2002 | WO2001028545A9 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 08/15/2002 | WO2001013935A3 Modulation of the blood-brain barrier transporter for leptin |
| 08/15/2002 | US20020111590 Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
| 08/15/2002 | US20020111488 Beta-substitued beta-aminoethyl phosphonate derivatives |
| 08/15/2002 | US20020111469 Polypeptide for use in the treatment of tumors, lung defects, inflammation and heart defects |
| 08/15/2002 | US20020111384 Administering levodopa, or mixture thereof |
| 08/15/2002 | US20020111383 Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| 08/15/2002 | US20020111381 Vision disorders; topical applying |
| 08/15/2002 | US20020111378 Inhibitors of IMPDH enzyme |
| 08/15/2002 | US20020111370 Compounds useful as antibacterial agents |
| 08/15/2002 | US20020111364 ABCA-1 elevating compounds |
| 08/15/2002 | US20020111362 Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| 08/15/2002 | US20020111359 Side effect reduction of narcotics |
| 08/15/2002 | US20020111347 Nervous system disorders |
| 08/15/2002 | US20020111345 Use of taurolidine to treat tumors |
| 08/15/2002 | US20020111337 Use of an aldosterone receptor antagonist to improve cognitive function |
| 08/15/2002 | US20020111336 Topical composition |
| 08/15/2002 | US20020111328 Anticancer, antitumor agent |
| 08/15/2002 | US20020111327 Method and compositions for treating the inflammatory response |
| 08/15/2002 | US20020111315 Synergistic mixture with antilipemic agent |
| 08/15/2002 | US20020111306 DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
| 08/15/2002 | US20020111292 Bone disorders, alopesia |
| 08/15/2002 | US20020111290 Calibration of chemokine or receptor expression; medical diagnosis |
| 08/15/2002 | US20020110895 Nucleotide sequences coding enzymatic polypeptide for use in treatment of thrombosis and in the immune defects |
| 08/15/2002 | US20020110889 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/15/2002 | US20020110888 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/15/2002 | US20020110858 Lymphocytic membrane proteins |
| 08/15/2002 | US20020110853 Polypeptide; for use in the treatment of tumors |
| 08/15/2002 | US20020110841 Regulation of cell growth by MUC1 |
| 08/15/2002 | US20020110840 Detecting modulators of interferon generation; obtain cells, incubate with modulator, monitor concentration of inflammatory cytokine, amplified cytokine concentration indicates modulators |